The agreement enables a full tech transfer of the chikungunya vaccine for future supply to low- and middle-income countries.Expanded collaboration…
Company voluntarily withdraws IXCHIQ BLA and IND in the U.S. Continuing review of global product opportunity according to medical need and…
Saint-Herblain (France), Pune, (India), December 31, 2025 – Valneva SE (“Valneva” or “the Company”), a specialty vaccine company, and Serum…
FRANKFURT, Germany, Aug. 08, 2025 (GLOBE NEWSWIRE) -- In response to recent outbreaks of Chikungunya fever, Anbio Biotechnology has announced…
Saint Herblain (France), July, 11 2025 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced…